Conventional T cells, while highly potent effector cells in immune surveillance and destruction of malignant cells, exhibit inherent functional constraints that impact CAR-T therapy outcomes. Factors such as exhaustion after repeated antigen stimulation, limited persistence, and the immunosuppressive tumor microenvironment dampen their sustained anti-tumor activity. Moreover, limitations in trafficking to tumor sites, issues with cytokine release syndrome, and the risk of graft-versus-host disease in allogeneic CAR-T treatments add further complexity. The manufacturing process itself, which typically involves autologous T cell collection, genetic modification, and expansion, is time-consuming, costly, and often results in products with variable quality and efficacy.

In response to these challenges, scientific efforts have increasingly turned towards harnessing the unique properties of immune cells beyond conventional αβ T cells. This strategy, broadly designated as “CAR-X” cell engineering, leverages the diverse biology of alternative immune populations such as natural killer (NK) cells, invariant natural killer T (iNKT) cells, γδ T cells, and macrophages. Each of these cell types possesses distinct functional attributes that may complement or surpass the capabilities of traditional CAR-T cells. Consequently, CAR-X therapies promise to enhance clinical efficacy, reduce side effects, and enable applications across a broader spectrum of diseases including solid tumors, infectious diseases, and autoimmune disorders.

Natural killer cells, for instance, play a vital role in innate immunity through their ability to recognize and eliminate virally infected or transformed cells without prior sensitization. Their intrinsic cytotoxicity and cytokine secretion profiles endow them with rapid effector functions. Notably, NK cells display a reduced risk of causing graft-versus-host disease, making them attractive candidates for allogeneic “off-the-shelf” CAR therapies. However, the limited in vivo persistence and challenges in genetic modification have historically hindered their development. Advances in gene editing and culture conditions are addressing these issues, enabling the generation of CAR-NK products with improved longevity and potent tumor-killing capacities.

Invariant natural killer T cells combine features of both innate and adaptive immunity with their semi-invariant T cell receptors recognizing glycolipid antigens presented by CD1d molecules. This unique biology allows iNKT cells to modulate the immune microenvironment profoundly, not only attacking tumor cells directly but also stimulating other immune effectors and overcoming immunosuppression. Engineering CARs into iNKT cells leverages these dual functionalities, offering a multifaceted therapeutic approach. Furthermore, iNKT cells exhibit lower alloreactivity, suggesting a safer profile for allogenic therapies.

Similarly, γδ T cells represent a distinct T cell lineage characterized by their γδ T cell receptors, which recognize stress-induced ligands independent of major histocompatibility complex (MHC) presentation. This property confers several advantages, including broad tumor recognition and the ability to function in an immunosuppressive milieu. CAR-γδ T cells can exploit these features to target cancers resistant to conventional therapies while benefiting from innate-like recognition pathways that limit immune escape. Ongoing innovations in ex vivo expansion and genetic engineering techniques are enabling scalable production of CAR-γδ T cell products.

Macrophages, traditionally viewed as phagocytic cells involved in tissue homeostasis and inflammation, are emerging as compelling vectors for CAR therapy due to their natural tumor infiltration and antigen-presenting capabilities. CAR-macrophages can potentially engulf and destroy tumor cells directly and orchestrate robust antitumor immune responses by activating adaptive immunity. Moreover, they can be engineered to remodel the tumor microenvironment, counteracting immune evasion mechanisms. Despite technical challenges in genetic modification and expansion, recent breakthroughs in viral and non-viral transduction methodologies have propelled CAR-macrophage development forward.

The design of CAR constructs tailored specifically to each immune cell type is another critical frontier in CAR-X engineering. Conventional CARs optimized for αβ T cells may not fully harness the unique signaling pathways and functional mechanisms of alternative immune cells. For example, CARs in NK cells often incorporate signaling domains derived from activating NK receptors like NKG2D or DAP12 to promote-specific activation, while CARs for macrophages integrate phagocytosis-inducing domains. Fine-tuning CAR architecture to synergize with endogenous signaling can substantially enhance efficacy and persistence within the host.

Manufacturing platforms are also evolving to accommodate the cell-specific requirements of CAR-X therapies. Whereas CAR-T cell production typically relies on lentiviral or retroviral transduction of T cells collected via leukapheresis, alternative approaches such as non-viral gene editing, mRNA electroporation, and stem cell differentiation protocols are being adapted. These tailored manufacturing strategies aim to improve scalability, safety profiles, and the timely generation of clinical-grade CAR-X products. Additionally, the potential to create universal donor cell banks using gene editing to prevent rejection or graft-versus-host disease presents a paradigm shift toward ready-to-use allogeneic cell therapies.

From a clinical perspective, early-phase trials integrating CAR-NK, CAR-iNKT, and CAR-γδ T cells have demonstrated encouraging safety profiles and preliminary efficacy signals, particularly in refractory hematological malignancies. The intrinsic biology of these cells contributes to attenuated cytokine release syndromes and neurotoxicity, which are common adverse events in CAR-T therapy. Moreover, solid tumor targeting, a notorious hurdle for CAR-T cells, may be more achievable with CAR-X cells due to their distinct trafficking and tissue-infiltrating capabilities. Accordingly, the clinical landscape is rapidly expanding, encompassing hematologic cancers, solid malignancies, viral infections, and even fibrotic or autoimmune diseases.

Despite these exciting developments, significant challenges remain in translating CAR-X technologies into widely available therapies. The heterogeneity of alternative immune cells necessitates optimization in expansion, persistence, and potency to achieve consistent therapeutic responses. Immune evasion by tumors, antigen heterogeneity, and immune suppression continue to pose obstacles that demand combinatorial or multifunctional engineering strategies. Concurrently, regulatory frameworks must adapt to the complexity of these novel therapies to ensure safety without stifling innovation.

In summary, CAR-X cell engineering represents a transformative frontier in immunotherapy, leveraging the diversity of the immune system to overcome the constraints of conventional CAR-T approaches. By harnessing the unique effector mechanisms and biological properties of NK cells, iNKT cells, γδ T cells, macrophages, and potentially other immune subsets, this paradigm expansion is poised to unlock new avenues for treating cancer and beyond. The iterative refinement of cell-specific CAR designs, manufacturing methods, and clinical applications heralds a future where personalized, effective, and safer cellular therapies redefine medicine.

As research accelerates, collaborations between academic institutions, biotechnology companies, and regulatory agencies will be paramount in propelling CAR-X therapies from experimental stages to mainstream clinical use. Integrative efforts that combine multi-omic profiling, machine learning, and synthetic biology will undoubtedly yield next-generation CAR constructs and cell products with enhanced functionality. In concert, ongoing clinical trials will illuminate the therapeutic landscape, refining indications, dosing regimens, and combination approaches to optimize patient outcomes.

Ultimately, the story of CAR-X cell engineering is one of innovation driven by the limitations of prior successes, a testament to the relentless pursuit of harnessing the immune system’s vast potential. The next decade promises to be pivotal, with the envisioned convergence of diverse immune cell engineering shaping a new chapter in immunotherapy that extends hope to millions of patients worldwide.

Subject of Research: Development and application of alternative immune cells engineered with chimeric antigen receptors (CAR-X) for enhanced immunotherapy.

Article Title: CAR-X cell engineering.

Article References:
Li, X., Lin, H., Liang, J. et al. CAR-X cell engineering. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00430-w

A highlight of this year’s presentations includes a major symposium by Dr. Stephen J. Forman, focused on the transformative potential of first-line chimeric antigen receptor (CAR) T cell therapy in adults diagnosed with acute lymphoblastic leukemia (ALL). CAR T cell therapy has revolutionized treatment paradigms for certain blood cancers by engineering a patient’s immune cells to specifically target and destroy malignant cells. Dr. Forman’s discussion will encompass clinical trial data and mechanistic insights into how initial CAR T therapy can optimize remission rates and durability for ALL patients, a population traditionally burdened with high relapse risk.

In parallel, Dr. Robert R. Jenq will deliver crucial insights into how the gut microbiome modulates patient responses to CAR T therapy. By studying the complex microbial ecosystems within patients, his research elucidates why some individuals experience remarkable therapeutic success while others encounter resistance or severe side effects. This emerging area leverages advances in metagenomics and immunology, positioning the microbiome as a key determinant of immunotherapeutic efficacy.

A standout study employs artificial intelligence (AI) to dissect gut microbiome differences implicated in early-onset colorectal cancer (CRC), a phenomenon increasingly diagnosed in younger adults. By integrating microbiome sequencing data with tumor genomics, clinical features, and social determinants of health, investigators applied sophisticated AI models to reveal reduced microbial diversity and distinct compositional shifts associated with early disease development. These findings, spearheaded by doctoral candidate Sophia Manjarrez and senior author Dr. Enrique Velazquez-Villarreal, highlight the multifactorial etiology of CRC and underscore the importance of a systems biology approach to uncover hidden biological signatures.

Another pivotal contribution from City of Hope researchers uncovers a heretofore unrecognized molecular pathway underpinning immune resistance in microsatellite-stable (MSS) colorectal cancers, which constitute the majority of CRC cases yet remain largely refractory to immunotherapy. This pathway centers on the RNA-modifying enzyme NAT10 and its interaction with the oncogene MYC. Enhanced NAT10 activity drives autophagy-mediated degradation of MHC class I molecules, essential components for T cell recognition of tumor cells. Disrupting this axis restores immune visibility of cancer cells, potentiating responses to checkpoint blockade in preclinical models. These discoveries, presented by Dr. Junyong Weng and led by Dr. Ajay Goel, offer promising therapeutic targets to overcome a major barrier in CRC treatment.

In the domain of hematologic malignancies, City of Hope’s research reveals a critical metabolic dependency in acute myeloid leukemia (AML). The protein eIF4A1 emerges as a linchpin in leukemia cell metabolism, facilitating the synthesis and utilization of nutrients necessary for unchecked proliferation. Inhibition of eIF4A1 not only impedes cellular energy production and protein translation but also translates into significant leukemia regression and survival benefits in animal models. This metabolic vulnerability, discussed by visiting researcher Xiaoxu Zhang and principal investigator Dr. Rui Su, may herald a new avenue for AML therapy by integrating metabolic repression with conventional treatments.

Advances in AI applications continue to permeate cancer immunology, exemplified by a novel model that predicts immune system targets with greater precision. This approach integrates structural predictions of peptide-MHC complexes derived from AlphaFold 3 with geometry-aware machine learning frameworks, enhancing epitope identification even when training data is limited. By refining how immune epitopes are predicted, the model may accelerate the development of personalized cancer vaccines and immunotherapies, addressing one of immunotherapy’s fundamental challenges — identifying the peptides that effectively elicit T cell responses. The work, presented by Dr. Kamel Lahouel and senior author Dr. Cristian Tomasetti, underscores the synergy between AI and experimental immunology.

City of Hope’s presence at the AACR Annual Meeting also features late-breaking poster sessions revealing novel insights into cancer disparities and immune mechanisms. For instance, spatial transcriptomics applied to endometrial cancer in African American women uncovers distinct molecular and immune pathway alterations, which may inform tailored therapeutic strategies. Additionally, studies on variations in cancer screening rates influenced by housing status and ethnicity post-implementation of targeted healthcare strategies highlight the crucial intersection of social determinants and oncologic outcomes.

The recognition of City of Hope’s scientists with multiple awards, including Early-Career Scholar and AACR Faculty Scholar honors, attests to the institution’s commitment to fostering innovative research leadership. These accolades also reflect the broader scientific community’s acknowledgment of the transformative potential of the studies being presented.

Collectively, these presentations illustrate City of Hope’s integrated approach to cancer research, encompassing molecular biology, immunology, computational modeling, and social sciences. Emphasizing translational relevance, the institution’s work aims to bridge laboratory discoveries with clinical applications, ultimately improving patient prognosis and quality of life. By embracing advanced AI, novel therapeutic targets, and comprehensive patient profiling, City of Hope is helping to define the future landscape of precision oncology.

At the heart of these endeavors lies an overarching philosophy: cancer is a multifaceted disease requiring holistic, multidisciplinary strategies. The convergence of high-throughput data technologies, innovative computational frameworks, and molecular insights is reshaping how researchers understand tumor biology, immune evasion, and therapeutic resistance. City of Hope’s presentations at AACR 2026 are a testament to the power of this model, offering hope for new, more effective treatments for patients worldwide.

As the oncology community gathers at the AACR Annual Meeting, the City of Hope team’s contributions promise to stimulate scientific dialogue and catalyze next-generation cancer therapies. From CAR T cell innovations to microbiome-mediated immune modulation and AI-driven epitope prediction, their research exemplifies the bold strides being made to unravel cancer’s complexities and translate knowledge into cures.

Subject of Research: Cancer risk, treatment resistance, and emerging therapeutic strategies in solid and blood cancers, incorporating microbiome analysis, molecular pathways, cancer metabolism, and AI-driven immunotherapy prediction.

Article Title: City of Hope Unveils Pioneering Cancer Research at AACR Annual Meeting 2026: AI, Microbiome, Metabolism, and Immunotherapy Breakthroughs

News Publication Date: 2026

Web References:
– https://www.cityofhope.org/
– https://www.abstractsonline.com/pp8/#!/21436/
– https://www.tgen.org/

References: Not specified in detail within the original content.

Image Credits: Not provided.

Keywords: cancer research, oncology, CAR T cell therapy, acute lymphoblastic leukemia, microbiome, colorectal cancer, immunotherapy resistance, NAT10, MYC, acute myeloid leukemia, metabolism, eIF4A1, artificial intelligence, peptide-MHC prediction, cancer vaccines, AACR Annual Meeting 2026, City of Hope

The infusion of funds from the Greenebaum family will predominantly support pioneering faculty research at the University of Maryland School of Medicine (UMSOM), bolstering efforts to develop cutting-edge cancer therapies. A major focus will be on immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapies, which have revolutionized treatment paradigms in hematologic malignancies and are now being explored aggressively for efficacy against solid tumors. This strategy involves reprogramming a patient’s immune cells to recognize and eradicate cancer cells with heightened specificity, offering hope for treating cancers that have historically been resistant to conventional approaches.

Beyond therapeutic innovations, the endowment will also strengthen survivorship programs at UMGCCC. Emerging wearable technologies capable of continuous physiological monitoring will be integrated into patient care strategies to optimize quality of life for cancer survivors. Personalized supportive care, including tailored nutritional regimens and psychosocial resources, will form a crucial component in enhancing long-term outcomes and mitigating treatment-related toxicities. This holistic approach underscores the center’s commitment to not only prolong lives but also improve the lived experience of patients beyond their clinical treatment.

As UMGCCC prepares for a significant physical expansion with its relocation to the Stoler Center for Advanced Medicine scheduled for fall 2026, the family’s donation assumes added significance. The new facility’s lobby will bear the Greenebaum name, symbolizing their enduring impact on the institution. The Stoler Center will house state-of-the-art laboratories, patient care suites, and clinical trial infrastructure designed to facilitate seamless translational research and multidisciplinary collaboration, ultimately accelerating the bench-to-bedside delivery of novel therapies.

Michael Greenebaum, scion of the Greenebaum family and an influential philanthropist, articulated the familial dedication behind the gift. Marking the 30th anniversary of the original donation, he emphasized that the contribution empowers the center to meet the escalating demand for expert oncology care in Maryland and its surrounding regions. The family’s longstanding involvement exemplifies how philanthropy can catalyze scientific breakthroughs and foster comprehensive patient-centric cancer care.

The Greenebaum family’s involvement extends beyond financial support. Michael Greenebaum serves as Chair of the University of Maryland School of Medicine’s Board of Visitors and sits on the UMGCCC Board of Advisors. He is also the founder of the Maryland Half-Marathon & 5K, which has raised over $8 million for the center, demonstrating an innovative approach to community engagement in cancer fundraising. This multi-faceted participation underscores the synergistic relationship between leadership, philanthropy, and research advancement.

The foundational success story of Marlene Greenebaum’s battle with breast cancer is intertwined with pioneering research at UMGCCC. She benefited from treatment with an aromatase inhibitor, a type of hormone therapy developed by Angela Brodie, PhD, a leading breast cancer researcher associated with the cancer center. Aromatase inhibitors function by blocking the enzyme aromatase, which converts androgens to estrogens, thereby reducing estrogen levels that fuel hormone receptor-positive breast cancers. This therapeutic breakthrough has become a standard of care globally, emblematic of how translational science at academic centers can alter clinical practices.

Leadership at UMGCCC recognizes the critical importance of sustained philanthropic support. Dr. Taofeek K. Owonikoko, the center’s Executive Director, noted that continuous funding is imperative for maintaining the momentum of clinical trials, which now number over 450 and represent a doubling from earlier years. These trials explore next-generation agents, combination immunotherapies, precision oncology approaches, and modalities aimed at overcoming tumor microenvironment-mediated resistance pathways. Such a robust clinical pipeline positions the center as a leader in oncology innovation.

UMGCCC’s research budget exceeds $130 million annually, reflecting its stature as a premier academic and research institution. The breadth of oncology clinical and basic research encompasses molecular biology, genomics, immunology, bioinformatics, and population health studies. The center’s faculty conduct extensive investigations into tumor biology, mechanisms of metastasis, and the development of novel biomarkers to enable early detection and therapeutic responsiveness. This comprehensive research spectrum embodies a systems biology approach to conquering cancer’s complexity.

The clinical environment benefits enormously from integration with UMGCCC’s basic science enterprises. The reciprocal relationship facilitates rapid hypothesis testing and functional validation of emerging targets in vivo through patient-derived xenograft models and organoid cultures. Moreover, the multidisciplinary teams comprising oncologists, surgeons, radiologists, pathologists, and data scientists collaborate intensively to tailor individualized treatment regimens, reinforcing the precision medicine paradigm.

Maryland’s University of Maryland Medical Center (UMMC), the flagship hospital in the 11-hospital University of Maryland Medical System (UMMS), serves as the clinical anchor for UMGCCC. UMMC’s advanced infrastructure supports high-complexity procedures, including solid organ transplantation and sophisticated imaging modalities vital for cancer diagnosis and management. The integration of clinical care and research fosters an ecosystem that translates scientific discoveries swiftly into standard practice, benefiting thousands of patients annually.

The upcoming expansion into the Stoler Center also represents a strategic bet on the future of oncology, emphasizing seamless integration of digital health technologies, telemedicine capabilities, and patient navigation services to improve access and adherence to cancer care protocols. The center’s mission aligns with global efforts to reduce cancer mortality through innovation while addressing survivorship challenges in an aging population that increasingly confronts late effects of cancer treatment.

In conclusion, the recent $5.5 million gift from the Marlene and Stewart Greenebaum Family Foundation marks a significant milestone for the University of Maryland Greenebaum Comprehensive Cancer Center. This philanthropic investment supports transformative cancer research, accelerates development of breakthrough therapies like CAR T-cell treatment for solid tumors, and enhances survivorship programs through advanced wearable technologies and tailored clinical support. The planned move to the Stoler Center for Advanced Medicine will bolster these efforts, situating UMGCCC to remain at the vanguard of cancer care and research. The Greenebaum family’s enduring legacy continues to inspire scientific innovation and exceptional patient care, reaffirming the profound impact of philanthropy in advancing the fight against cancer.

Subject of Research: Cancer research and treatment innovations at the University of Maryland Greenebaum Comprehensive Cancer Center, including immunotherapies and survivorship care.

Article Title: University of Maryland Greenebaum Comprehensive Cancer Center Receives $5.5 Million Gift to Accelerate Cancer Research and Care Expansion

News Publication Date: Not specified in the source content.

Web References:

• https://www.umms.org/umgccc
• https://www.umms.org/about/leadership/mohan-suntha
• https://www.medschool.umaryland.edu/profiles/gladwin-mark/
• https://www.umms.org/ummc/about/leadership/bert-w-omalley
• https://www.umms.org/find-a-doctor/profiles/dr-taofeek-kunle-owonikoko-md–phd-1578770871
• https://www.umms.org/ummc/about/leadership/heather-culp
• https://www.medschool.umaryland.edu/
• http://www.umm.edu/
• http://www.umms.org/

Image Credits: University of Maryland School of Medicine

Keywords: Cancer research, Immunotherapy, CAR T-cells, Survivorship care, Philanthropy, University of Maryland Greenebaum Comprehensive Cancer Center, Translational medicine, Clinical trials, Oncology innovation, Comprehensive cancer center

The origin of CAR-T therapy lies in genetically reprogramming a patient’s own T cells to seek and destroy malignant or virally infected cells. This is achieved by extracting T cells, engineering them with CAR constructs that precisely target specific antigens, and reinfusing these altered cells back into the patient’s system. Despite its initial clinical successes—marked by rapid remission in many blood cancer patients—the longevity of CAR-T effects has been a consistent challenge. Cells gradually lose their cytotoxic vigour, and approximately half of recipients face cancer relapse, highlighting the need for a durable cell product that supports long-term immune surveillance.

Equally compelling is the intervention’s application against HIV, a virus notorious for hiding in latent reservoirs within immune cells. Current antiretroviral therapies (ART) suppress active viral replication but do not purge these reservoirs, necessitating lifelong medication with associated systemic toxicities. CAR-T cells engineered to not only attack infected cells but also persist long-term could offer a functional cure, controlling the virus in the absence of continuous drug therapy, a feat yet to be realized.

Central to this innovation is the design and implementation of a tri-cytokine fusion protein scaffold dubbed HCW9206, integrating IL-7, IL-15, and IL-21. These cytokines individually are integral to T cell homeostasis, survival, and memory formation, but their fusion into a single scaffold synergistically amplifies signals promoting the generation of durable CAR-T populations enriched in T memory stem cells (T_SCM). T_SCM cells represent a unique subset distinguished by their longevity, self-renewal capacity, and ability to differentiate into potent effector cells, thereby maintaining continuous immune protection.

The engineering process yields a CAR-T product with over 50% T_SCM phenotype cells, a stark contrast to the less than 5% achieved by conventional manufacturing. This shift profoundly impacts functional durability since T_SCM cells sustain prolonged antigen-specific responses, reconstituting the active cytotoxic pool over extended periods. The implications of this are pivotal for preventing relapse and managing chronic infections, where sustained immune pressure is critical.

Experimental murine models of human leukemia provided compelling validation. While both standard and scaffold-fabricated CAR-T cells initially eradicated cancerous cells effectively, only the multi-cytokine scaffold-modified cells re-expanded after subsequent tumor re-challenge, demonstrating a robust recall response that prevented disease resurgence. This property underscores the scaffold’s capacity to cultivate a cellular product capable of immunological memory akin to natural adaptive immunity.

Parallel investigations in a humanized mouse HIV model revealed that scaffold-engineered CAR-T cells manifested significantly greater antiviral activity, eradicating more HIV-infected cells compared to their standard counterparts. Notably, when applied to T cells derived from HIV-positive patients, the multi-cytokine scaffold methodology successfully eliminated infected cells, signaling readiness for translational adaptation.

Beyond therapeutic efficacy, this research suggests a refinement in CAR-T manufacturing protocols that could redefine the logistical and clinical paradigms of cell-based therapies. By incorporating cytokine signals that guide differentiation towards a stem memory phenotype at the point of ex vivo expansion, clinicians may enhance both the efficacy and sustainability of treatments, reducing relapse rates and potentially minimizing the need for repeated cell infusions.

Harris Goldstein, M.D., the study’s senior author and a leading figure in immunotherapy, emphasizes the transformative potential of this discovery. He envisions future CAR-T treatments not simply as transient tumor killers but as living drugs capable of self-renewal and persistent vigilance. This paradigm shift offers hope for cancer patients grappling with relapse and for millions living with HIV who currently require lifelong medication.

Further reinforcing the translational promise, the multi-cytokine scaffold’s design leverages subtle immunobiological principles. Each incorporated cytokine plays distinct but complementary roles: IL-7 fosters naive and memory T cell survival; IL-15 supports proliferative fitness and longevity; and IL-21 enhances functionality and memory phenotype maintenance. Together, by structurally uniting these cytokines, the scaffold creates a molecular milieu that biases the T cell culture towards a stem-like, self-maintaining state.

Notably, this approach addresses a critical manufacture bottleneck—current culture methods often drive T cells towards terminal differentiation or exhaustion, limiting their lifespan and efficacy. The cytokine fusion scaffold circumvents this by promoting a less differentiated, more therapeutically advantageous phenotype, a remarkable feat in cellular engineering that melds immunology with protein design.

The study was authored by a collaborative team spanning multiple institutions, including Einstein, Rockefeller University, HCW Biologics, Caring Cross, and the University of Texas Southwestern Medical Center. Funding was provided by the National Institutes of Health, underlining the significance of public investment in pioneering biomedical research.

Looking ahead, this cytokine fusion scaffold strategy may redefine standards across the burgeoning CAR-T field. The capacity to engineer CAR-T cells with intrinsic resilience and memory opens new horizons for tackling not only hematologic malignancies but infectious diseases characterized by persistent reservoirs or chronic infection. Moreover, it invites exploration of similar scaffold-based approaches to fine-tune cellular therapies targeting solid tumors and autoimmune disorders.

By revitalizing CAR-T cell longevity through molecular engineering of the ex vivo environment, the study heralds a future where living drugs maintain robust, durable antitumor and antiviral immunity. Such advancements push the envelope of personalized medicine, with the promise of delivering sustained remission, reduced relapse, and functional cures to patients worldwide.

Subject of Research: Animals

Article Title: IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR-T cells enriched in long-lived T memory stem cells

News Publication Date: 13-Mar-2026

Image Credits: Albert Einstein College of Medicine

Keywords: Blood cancer, Leukemia, Cancer, Immune cells

CAR-T cell therapy involves engineering a patient’s T cells, a subset of immune cells responsible for identifying and killing infected or malignant cells, to express synthetic receptors that specifically recognize tumor-associated antigens. This genetic modification endows T cells with the ability to locate and destroy cancer cells that would otherwise evade natural immune surveillance. The method represents a paradigm shift, offering precise, targeted attack mechanisms that minimize the collateral damage commonly associated with chemotherapy and radiation.

Michel Sadelain’s work in the 1990s laid the foundation for this approach by improving the viability and effectiveness of CAR constructs. Building on the initial concept introduced by Zelig Eshhar, who proposed the CAR concept in 1993, Sadelain’s team engineered second-generation CAR-T cells capable of proliferating and maintaining their cancer-killing function in vitro. A landmark 2003 study demonstrated that human CAR-T cells targeting the CD19 antigen eradicated leukemic cells in animal models, establishing a critical proof-of-concept.

Simultaneously, Carl June’s research expanded the clinical horizon by demonstrating that genetically modified T cells could survive long-term in human patients. Initially focusing on AIDS, June showed that engineered T cells could persist within the human body, producing durable immune responses. This persistence was essential for cancer therapy, where eradication requires sustained immune vigilance. These findings catalyzed the initiation of clinical trials using CAR-T cells to treat refractory leukemias.

The clinical successes of these trials surpassed expectations. Notably, June’s 2010 experimental treatment administered CAR-T cells to two late-stage leukemia patients, achieving remarkable results. One patient experienced complete remission with a single infusion and sustained CAR-T cell presence for a decade, illustrating the therapy’s potential for long-term disease control. These outcomes were more compelling than those observed in animal models, reflecting the complex interactions within the human immune system.

Building on these clinical breakthroughs, regulatory authorities recognized CAR-T therapy’s transformative promise. The U.S. Food and Drug Administration approved the first CAR-T treatment in 2017 for pediatric and young adult patients with refractory acute leukemias and certain lymphomas, followed by approval in the European Union. To date, over 50,000 patients worldwide have benefited from these authorized therapies, underscoring their profound impact on hematologic oncology.

Internationally, centers of excellence are advancing CAR-T technologies. In Spain, Manel Juan spearheaded efforts to adapt and implement CAR-T therapies at Hospital Clínic de Barcelona. By integrating academic preclinical research, manufacturing, and clinical application, these initiatives have enhanced accessibility and reduced costs, providing treatment to hundreds of patients. Further, strategies to optimize affordability are under development globally, including approaches that bypass traditional cell extraction by directly delivering CAR-encoding materials into patients, as well as off-the-shelf allogeneic therapies.

Despite successes in blood cancers, CAR-T therapies face significant challenges in treating solid tumors such as breast, colon, pancreatic, and lung cancers. These tumors present a more hostile microenvironment and greater antigenic heterogeneity, making target identification and immune cell infiltration more difficult. Clinical trials in solid tumors have so far produced disappointing results, highlighting the need for novel designs and combinatorial strategies to overcome immunosuppressive tumor niches.

Nonetheless, optimism remains high. Hundreds of laboratories worldwide are intensively investigating improved CAR constructs, multi-target approaches, and combination treatments to surmount the barriers posed by solid tumors. As understanding of tumor biology deepens, the next decade may witness CAR-T therapy conquering a broader spectrum of malignancies, bringing the promise of personalized cellular immunotherapy closer to reality.

Beyond oncology, the versatility of CAR-T cells extends into autoimmune and infectious diseases. By targeting CD19, which is expressed on B cells responsible for antibody production, CAR-T therapies have shown remarkable efficacy in autoimmune disorders such as lupus, where pathogenic antibodies damage host tissues. This application has inspired a wave of clinical studies exploring CAR-T interventions for other autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

In infectious diseases, CAR-T cell strategies aim to eradicate persistent viral reservoirs. Early treatments in HIV-positive patients demonstrated promise, offering a potential functional cure where antiretroviral therapy only manages chronic infection. Similarly, emerging research explores CAR-T therapies against infections like COVID-19 and non-infectious conditions involving immune dysregulation. These pioneering efforts illustrate the expansive potential of genetically engineered T cells as versatile therapeutic agents.

The innovation brought forth by June and Sadelain represents a watershed moment in medical science, often described as the advent of the first “living drug.” Differentiating from conventional pharmaceuticals requiring repeated administration, CAR-T therapies leverage the patient’s own immune cells, genetically programmed to persist and provide long-term protection. This precision and durability redefine therapeutic paradigms and herald new frontiers in precision medicine.

Carl H. June, a biologist and physician trained at the United States Naval Academy and Baylor College of Medicine, currently directs the Center for Cellular Immunotherapies at the University of Pennsylvania. Michel Sadelain, with medical and immunology training spanning the University of Paris and University of Alberta, leads cancer cell therapy initiatives at Columbia University. Their complementary expertise and pioneering research have collectively transformed the landscape of cancer immunotherapy and reengineered our understanding of immune system capabilities.

As CAR-T technology continues to evolve, the scientific community eagerly anticipates broader applications and enhanced efficacy. With ongoing research addressing cost, accessibility, and therapeutic breadth, CAR-T therapy stands at the forefront of medical innovation, poised to revolutionize treatment not only for cancer patients but for a myriad of conditions where immune modulation holds the key to healing.

Subject of Research: CAR-T cell therapy, cancer immunotherapy, genetic engineering of immune cells

Article Title: Revolutionary Advances in CAR-T Cell Immunotherapy: From Blood Cancers to New Frontiers

News Publication Date: Not specified

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/0f23512c-57ac-49b8-b5ae-7fd6a312e89f/Rendition/low-res/Content/Public

Image Credits: From left to right: Carl H. June (© University of Pennsylvania) and Michel Sadelain

Keywords: Cancer immunology, clinical medicine, immunotherapy, immunogenetics, immune cells, immunology

Historically, CAR T-cell therapy trials systematically excluded patients with CNS involvement due to a well-founded concern about heightened neurologic toxicity. The administration of CD19-directed CAR T cells has been associated with neurologic adverse effects, ranging from mild confusion to severe encephalopathy, which are collectively termed immune effector cell-associated neurotoxicity syndrome (ICANS). Given the delicate and critical nature of the CNS and the pathological involvement of lymphoma in this compartment, conventional wisdom dictated a conservative approach, precluding CNS lymphoma patients from receiving this innovative immunotherapy. Nonetheless, early anecdotal evidence and data from studies in acute lymphoblastic leukemia and other lymphomas suggested that CAR T cells are capable of trafficking across the blood-brain barrier, infiltrating the CNS, and exerting their cytotoxic effects on malignant cells within this sanctuary site, prompting the need for systematic research.

Dana-Farber spearheaded a pilot, investigator-initiated trial designed to assess the safety and feasibility of axicabtagene ciloleucel in patients diagnosed with either primary or secondary CNS lymphoma that was relapsed or refractory to standard treatments. The study meticulously enrolled 18 patients in a staged manner with intensive monitoring protocols to identify dose-limiting toxicities and neurologic complications. The outcomes from this trial demonstrated not only manageable safety profiles but also encouraging signals of efficacy sufficient to persuade regulatory bodies of the therapy’s viability. These data formed the backbone of the FDA’s decision to rescind the previous exclusionary clause, thus formally endorsing the therapeutic use of axi-cel in this challenging context.

This regulatory update is transformative because it challenges and redefines our understanding of CAR T-cell therapy’s limitations and potential. Eligible patients with diffuse large B-cell lymphoma (DLBCL) confined to the CNS now have a path to receive a personalized, cellular immunotherapy option following one or more prior lines of treatment. This shift might herald a new therapeutic era for those suffering from primary CNS lymphoma, who have historically faced dismal prognoses and scant treatment alternatives.

The clinical implications of these findings are profound. Dr. Lakshmi Nayak, Director of Dana-Farber’s Center for CNS Lymphoma, presented these data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting that nearly half of the patients treated with axi-cel in this cohort were alive and free from disease relapse at approximately one year post-therapy. While this represents a significant therapeutic breakthrough, Dr. Nayak emphasized the need for longitudinal studies to fully elucidate the durability of these responses and to assess the potential for long-term remission or cure in this population.

The success of this research at Dana-Farber is the culmination of years of careful, hypothesis-driven clinical investigation and multidisciplinary collaboration. Neuro-oncology, immunology, and cell therapy experts combined efforts to navigate the complexities of delivering engineered T cells into a previously deemed ‘immune-privileged’ site. The investigators employed rigorous patient selection criteria and bespoke safety monitoring frameworks to mitigate the risks while maximizing therapeutic benefit.

Understanding the mechanism behind CAR T-cell trafficking into the CNS involves appreciating the dynamic interplay between immune effector cells and the CNS microenvironment. The blood-brain barrier traditionally restricts passage of large molecules and cells to protect the brain from systemic insults. However, inflammation induced by lymphoma and CAR T-cell activation can transiently increase permeability, allowing CAR T cells to infiltrate the CNS parenchyma, surveil, and eliminate neoplastic cells. This ability to breach CNS sanctuaries marks a pivotal shift in cellular immunotherapy paradigms and widens the therapeutic targeting landscape.

Neurologic toxicity remains a key consideration. The research delineated strategies to identify early signs of ICANS and implemented interventions such as steroids and supportive care to manage these adverse events effectively. Encouragingly, the toxicity profile within this CNS lymphoma cohort was comparable to or only slightly elevated from that observed in systemic lymphoma patients without CNS involvement, alleviating earlier apprehensions about unacceptable risk.

From a translational science perspective, the axicabtagene ciloleucel FDA label change embodies the power of investigator-initiated studies to influence regulatory policy and clinical practice. The successful generation of prospective safety data, coupled with pharmacodynamic and clinical outcome measures, underscores the importance of academic institutions in driving innovation beyond industry-sponsored trials. Dana-Farber’s initiative illustrates how focused research efforts can break down long-standing barriers to care and redefine therapeutic standards.

With this important development, clinicians managing neuro-oncology and hematologic malignancies now have an expanded armamentarium supported by robust clinical evidence. The updated labeling allows for more inclusive treatment decisions that incorporate novel immunotherapies earlier in the disease course for primary CNS lymphoma patients, who were previously considered ineligible for such approaches. This democratization of CAR T-cell therapy access promises improved survival and quality of life for patients grappling with this particularly lethal disease subtype.

Looking ahead, ongoing and future investigations are poised to refine patient selection criteria, optimize conditioning regimens, and evaluate combinational approaches that might enhance CAR T-cell efficacy specifically within the CNS milieu. Additionally, molecular and cellular analyses derived from treated patients will offer deeper insights into resistance mechanisms and potential biomarkers predictive of response or toxicity. These efforts will collectively inform next-generation cellular therapies engineered to overcome current limitations.

In sum, the FDA’s approval of an expanded indication for axicabtagene ciloleucel represents a watershed moment in cancer immunotherapy. It validates the feasibility of harnessing engineered T cells to combat malignancies within the CNS, provides a much-needed therapeutic option for a highly vulnerable patient population, and exemplifies how rigorous clinical investigation can drive meaningful regulatory and clinical progress. As CAR T-cell technologies continue to evolve, their integration into the management of CNS lymphoma promises to accelerate therapeutic breakthroughs, ultimately translating into enhanced patient outcomes and survival.

Subject of Research:
FDA label update enabling axicabtagene ciloleucel (Yescarta) use in primary central nervous system lymphoma based on Dana-Farber’s clinical research.

Article Title:
FDA Expands Access to CAR T-Cell Therapy for Primary Central Nervous System Lymphoma Following Dana-Farber-Led Research

News Publication Date:
2024

Web References:
http://www.dana-farber.org/
https://www.dana-farber.org/find-a-doctor/caron-a-jacobson
https://www.dana-farber.org/find-a-doctor/lakshmi-nayak

Keywords:
Adoptive T cell therapy, Lymphoma, Central nervous system lymphoma, CAR T-cell therapy, Axicabtagene ciloleucel, Immune effector cell-associated neurotoxicity syndrome, Diffuse large B-cell lymphoma, Cancer immunotherapy, Hematologic malignancies, Cell-based therapy

Chimeric Antigen Receptor T (CAR-T) cell therapy has made remarkable strides since its inception, transforming the landscape of hematological malignancies. However, its effectiveness in solid tumors has been hampered by various factors, including the immunosuppressive tumor microenvironments and the tumor’s ability to evade immune detection. The introduction of cutting-edge designs for CAR-T cells that can specifically target tumor-associated antigens, which are overexpressed in cancer cells, signifies a paradigm shift in how these therapies can be deployed for enhanced patient safety and efficacy.

Researchers, led by Lei et al., have embarked on an ambitious journey to refine CAR-T cell therapy by integrating advanced genetic and computational techniques. By thoroughly analyzing various tumors, they identified specific markers and microenvironmental signals that can be exploited to condition CAR-T cells for improved functionality. This meticulous approach not only seeks to bolster the resilience of CAR-T cells but also aims to ensure their sustainability within the harsh tumor milieu.

At the heart of this new design is the customization of CAR-T cells to express multiple receptors that can target tumor-specific antigens. This dual-targeting mechanism is critically important for overcoming the limitations often faced by conventional CAR-T therapies, which are designed for a single antigen target. The researchers highlight that this innovative aspect allows for a greater likelihood of tumor elimination and reduces the chance of tumor relapse, which is a significant hurdle in current cancer therapies.

One of the pioneering elements of this next-generation CAR-T cell design is its adaptability based on real-time tumor assessments. By using advanced imaging and molecular profiling techniques, the research team is able to continuously update the CAR-T cells’ targeting properties according to the evolving characteristics of the tumor. This adaptability ensures that the therapy remains effective, even as tumor cells change over time, thereby enhancing the durability of the treatment.

The study also emphasizes the crucial role of the tumor microenvironment in conditioning CAR-T cells for success. By identifying various immunosuppressive factors present within tumor tissues, the researchers were able to devise strategies that either negate these suppressive signals or modify CAR-T cells to function optimally in such hostile conditions. This approach is expected to significantly reduce the risks of CAR-T cell exhaustion, a common challenge in current treatment paradigms.

Moreover, the integration of advanced CRISPR-based gene editing techniques allows for precise modifications to CAR-T cells, enhancing their cytotoxic capabilities while minimizing off-target effects. By selectively knocking out genes associated with negative regulatory pathways, the engineered CAR-T cells exhibit heightened anti-tumor activity. This level of intervention marks a historic moment in therapeutic design, where tailored modifications can deeply influence treatment outcomes.

The anticipated benefits of this next-generation CAR-T cell therapy extend beyond solid tumors to include multiple cancer types, potentially impacting a vast patient population. With the ongoing challenges posed by tumor heterogeneity, this versatile design aims to overcome barriers that have traditionally limited the efficacy of immunotherapies in various forms of cancer. As these innovative strategies are validated through clinical trials, they hold the potential to salvage lives that would have been deemed irretrievably lost to cancer.

Another critical area of focus in the study is the safety profile of the next-generation CAR-T therapies. By engineering cells to selectively target tumor cells while sparing healthy tissues, the researchers aim to minimize the often severe side effects associated with traditional CAR-T therapies, such as cytokine release syndrome and neurotoxicity. Enhanced safety measures are essential for broadening patient eligibility and increasing overall acceptance of CAR-T therapies in standard oncological practices.

The future directions proposed by Lei and colleagues encompass not only the intrinsic improvements to CAR-T cells but also extend to developing combination therapies. By integrating checkpoint inhibitors or additional immunomodulatory agents, the enhanced CAR-T cells can be further activated, facilitating a multi-pronged approach to combat cancer. This combination strategy is projected to tap into multiple biological pathways, streamlining the immune response against tumors and enhancing eradication rates.

As the research heads toward clinical application, the investigators emphasize the importance of collaboration across disciplines, from bioinformatics to translational oncology. By fostering cross-disciplinary dialogue, the development of synergistic therapies that can overcome existing challenges in current treatment regimens becomes more feasible. Such collaborations will serve to expedite the realization of next-generation CAR-T therapy from the laboratory bench to the patient bedside, heralding a new era of personalized cancer treatment.

In conclusion, the innovative design of next-generation CAR-T cells poised to leverage tumor features represents a transformative milestone in the field of cancer immunotherapy. The ability to adapt to tumor dynamics and effectively target resistant cancer cells may very well reshape therapeutic strategies, leading to improved survival rates and enhanced quality of life for patients grappling with this relentless disease. As research progresses and clinical trials are set to commence, the promise of CAR-T advancements shines brightly, offering a beacon of hope for patients and clinicians alike in the struggling fight against cancer.

This seminal work is not merely a step forward but a leap toward a future where individualized cancer therapies become a standard, allowing for treatments that resonate with the unique profiles of each patient’s tumor landscape. With continuous efforts and rigorous research, the dream of curing cancer in all its forms could soon transcend from aspiration to reality.

Subject of Research: Next-generation CAR-T cell design leveraging tumor features

Article Title: Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy

Article References:

Lei, Y., Liu, N., Qin, D. et al. Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.
Mol Cancer (2025). https://doi.org/10.1186/s12943-025-02515-3

Image Credits: AI Generated

DOI: 10.1186/s12943-025-02515-3

Keywords: CAR-T cells, cancer immunotherapy, tumor microenvironment, personalized medicine, gene editing, tumor heterogeneity, combination therapies

ICANS presents a spectrum of neurological symptoms that can range from mild confusion and disorientation to severe manifestations such as seizures or coma. The pathophysiology behind this intriguing yet concerning syndrome continues to be a focus of intense scrutiny within the research community. As CAR T-cell therapy breaks new ground in cancer treatment, understanding ICANS becomes increasingly crucial for managing patient care and improving therapeutic outcomes.

One of the prevalent theories regarding the development of ICANS postulates that the rapid proliferation of CAR T cells leads to a robust inflammatory response, releasing a cascade of cytokines that may impact the central nervous system. High levels of these cytokines can penetrate the blood-brain barrier, leading to neuroinflammation and subsequent neurological symptoms. This cytokine release syndrome (CRS) often accompanies ICANS, further complicating the clinical picture.

Recent studies have illuminatingly detailed the surveillance of neurological side effects following CAR T-cell therapy. Researchers have identified potential risk factors that predispose certain patients to ICANS. Age, prior exposure to chemotherapy, the specific CAR construct used, and the degree of pre-existing neurological health are all variables that can influence the onset and severity of neurotoxicity. As our understanding deepens, it is clear that personalized treatment strategies must be developed to minimize occurrences of ICANS among susceptible populations.

In particular, the timing of ICANS onset is noteworthy. Symptoms can arise within a few days to weeks after the administration of CAR T cells, marking a key period when careful monitoring and intervention can be vital. Early identification and remediation of symptoms can significantly affect patient outcomes. Therefore, clinicians are now urged to implement routine neurological assessments at various intervals post-treatment—a shift that showcases the evolving nature of patient management in this age of advanced cancer therapies.

The intricate relationship between CAR T-cell therapy and ICANS further emphasizes the need for ongoing research. While clinical observation aids in understanding potential risks, animal model studies offer critical insights into the biological mechanisms underlying the syndrome. By examining how CAR T cells interact with neuroimmune pathways in preclinical models, researchers are developing a clearer picture of neurotoxic pathways, which could lead to specific therapeutic interventions aimed at mitigating symptoms.

Moreover, the therapeutic landscape is shifting towards the exploration of protocols that seek to prevent the onset of ICANS. These may include the use of adjunct therapies aimed at modulating the immune response without compromising the efficacy of CAR T-cell therapy. Drugs that target the overactive inflammatory response, such as tocilizumab, have shown promise in managing CRS and may also play a role in alleviating neurological symptoms associated with ICANS. This dual-pronged approach highlights the necessity of research to discover optimal supportive care alongside CAR T-cell administration.

As sectors of oncological care evolve with increasing speed, the integration of multidisciplinary teams becomes indispensable. Oncologists, neurologists, and immunologists must collaborate closely to foster a rich exchange of knowledge and expertise. This collaborative effort will ensure that CAR T-cell therapy’s benefits can be maximized while minimizing the adverse effects associated with neurotoxicity.

Additionally, patient education stands at the forefront of effective cancer care. Patients undergoing CAR T-cell therapy should be informed not only of the potential benefits but also the risks, including the possibility of developing ICANS. Clear communication regarding symptomatology and the importance of reporting neurological changes can empower patients, allowing for prompt medical intervention should complications arise.

In summary, while CAR T-cell therapy represents a beacon of hope for many facing recalcitrant malignancies, the associated development of immune effector cell-associated neurotoxicity syndrome remains a significant area of concern and research. As scientists decode the molecular underpinnings and risk factors of ICANS, there lies an opportunity to enhance patient management strategies, inform clinical guideline updates, and ultimately shape the future of CAR T therapies. This evolving landscape of precision oncology highlights the critical balance between efficacy and safety—a delicate equilibrium paramount for the successful integration of revolutionary cancer treatments into routine clinical practice.

The horizon of CAR T-cell therapy glistens with promise, yet it also casts shadows of potential complications like ICANS. Navigating the realms of therapeutic efficacy while being vigilant toward adverse events will determine the trajectory of patient care within oncology. Continued investigations into the complexities of CAR T-cell-induced neurotoxicity will undoubtedly enrich the knowledge base required to enhance patient outcome strategies and uphold the high standards of care that is paramount in the field of cancer treatment.

As we explore this multifaceted issue, the anticipated future of CAR T-cell therapy will depend not only on breakthroughs in therapeutic effectiveness but also on understanding and addressing the complexities of complications such as ICANS. The pathway forward remains bright, with collaborative efforts among researchers, clinicians, and patients paving the way.

Subject of Research: Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy.

Article Title: Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.

Article References:

Fatahichegeni, M., Ansarian, M.A., Wang, Y. et al. Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07646-1

Image Credits: AI Generated

DOI:

Keywords: CAR T-cell therapy, neurotoxicity, immune effector cells, cytokine release syndrome, cancer treatment.

The study emphasizes that AML is a particularly challenging malignancy due to its heterogeneity and resistance to conventional therapies. Unlike other leukemias, AML is characterized by a complex array of genetic mutations and epigenetic alterations, making it difficult to target effectively with standard chemotherapy and radiation. This high degree of variability among AML patients necessitates the exploration of innovative treatment modalities, such as CAR-T and CAR-NK cell therapies, which offer a more personalized and targeted approach to cancer treatment.

Central to the efficacy of CAR-T therapy is the engineering of T cells to express specific receptors that can recognize and bind to cancer cell antigens. The study highlights recent breakthroughs in identifying novel antigens that are uniquely expressed on AML cells and the potential for these targeted therapies to drastically improve patient outcomes. By harnessing the body’s immune response, CAR-T cells can be programmed to effectively target and eliminate malignant cells while preserving healthy tissue—a feat that has proven elusive with traditional treatments.

Meanwhile, CAR-NK cell therapy represents another promising frontier. Unlike T cells, NK cells are part of the innate immune system and can rapidly respond to a wide variety of tumors without being genetically engineered to recognize specific antigens. This distinction grants them a critical advantage; they are less likely to be affected by the tumor’s heterogeneity compared to T cells. The findings in the Wu et al. study underline the potential for CAR-NK cells to complement CAR-T therapies, providing a multifaceted approach to combating AML.

The research conducted by Wu and colleagues also delves into the significant role of the tumor microenvironment in AML. The microenvironment is often replete with immunosuppressive factors that can inhibit the effectiveness of immune therapies. This study reveals that a deeper understanding of the interactions between AML cells and their microenvironment is crucial for enhancing the efficacy of CAR therapies. By modifying the tumor microenvironment or adjusting treatment protocols to counteract its suppressive effects, researchers may unlock new avenues for successful AML treatments.

Moreover, the study discusses the challenges associated with manufacturing CAR-T and CAR-NK cells. The complexities involved in the ex vivo expansion and genetic modification of these cells represent a significant hurdle in bringing these therapies from the laboratory to the clinic. Researchers Wu, Shafiei, and Taghinejad advocate for the development of streamlined manufacturing processes that can ensure a consistent supply of high-quality cellular products for patients—a necessary advancement to scale these therapies for broader clinical applications.

In addition to manufacturing challenges, the study addresses issues surrounding the safety and potential side effects of CAR-T and CAR-NK therapies. While these therapies can lead to remarkable remissions in patients, they can also provoke severe immune-related adverse effects, such as cytokine release syndrome. The paper highlights ongoing research aimed at refining the specificity of CAR constructs and minimizing off-target effects, thereby enhancing patient safety while maintaining therapeutic efficacy.

As researchers continue to unravel the complexities surrounding AML, the study posits that collaboration across disciplines will be essential for advancing CAR-T and CAR-NK therapies. The integration of genomic analysis, bioinformatics, and personalized medicine will play a pivotal role in tailoring treatment plans to individual patients. This collaborative approach may not only improve outcomes for those with AML but also set a precedent for the treatment of other malignancies.

In light of these challenges and advancements, Wu et al. call for further clinical trials to evaluate the efficacy of CAR-T and CAR-NK therapies in AML. The promise these therapies hold cannot be understated; preliminary clinical data have demonstrated their potential to induce complete responses in heavily pre-treated patient populations. Continued investment in research and clinical development will be imperative in translating these findings into standard care practices.

The study also emphasizes the importance of patient selection in maximizing the benefits of CAR therapies. Identifying patients who are most likely to respond to these treatments, based on genetic profiling and disease characteristics, may significantly enhance treatment efficacy. By integrating biomarker analysis into clinical practice, physicians may be better equipped to customize treatment protocols that align with the unique biology of each patient’s AML.

Ultimately, the work of Wu, Shafiei, and Taghinejad signifies a turning point in the management of AML. The potential for CAR-T and CAR-NK cell therapies to change the treatment paradigm is immense, offering new hope to patients facing this devastating disease. As challenges remain, the contributions of this research not only break through barriers but also chart a path for future innovations in immunotherapy.

In conclusion, the future of AML treatment appears brighter with the advent of CAR-T and CAR-NK therapies. Through overcoming manufacturing hurdles, ensuring safety, and leveraging collaborative research, these therapies could redefine the standard of care for AML patients. The evolution of these strategies may pave the way for a new era in leukemia treatment, ultimately improving survival rates and quality of life for patients confronting this formidable disease.

Subject of Research: Acute Myeloid Leukemia (AML) and Immunotherapy
Article Title: CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future
Article References:

Wu, H., Shafiei, F.S., Taghinejad, Z. et al. CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future. J Transl Med 23, 1163 (2025). https://doi.org/10.1186/s12967-025-07151-5

Image Credits: AI Generated
DOI: 10.1186/s12967-025-07151-5
Keywords: CAR-T therapy, CAR-NK therapy, acute myeloid leukemia, immunotherapy, tumor microenvironment, treatment efficacy, personalized medicine, cytokine release syndrome.

CAR T cells represent a revolutionary approach in oncology, effectively turning a patient’s immune system into a tailored weapon against cancer. By genetically modifying T cells to express chimeric antigen receptors (CARs), researchers have enabled these immune cells to target and destroy malignant cells selectively. This technique has shown extraordinary success in curing patients suffering from previously untreatable blood cancers, such as specific types of leukemia and lymphomas. However, the broad application of this therapy remains challenging due to the fact that many patients do not respond favorably. This shortcoming is often attributable to the intrinsic limitations of T cells, which can diminish their effectiveness in the hostile tumor microenvironment.

The new study spearheaded by Paul Datlinger and his colleagues at CeMM has led to the creation of a transformative platform known as CELLFIE—short for CAR T cell engineering and high-content CRISPR screening technology. This comprehensive approach permits the systematic modification of CAR T cells at the genetic level, enabling researchers to screen for gene knockouts that improve the functionality and persistence of these therapeutic cells. Utilizing cutting-edge CRISPR technology, the researchers were able to test the impact of knocking out various human genes on CAR T cell performance, providing them with invaluable insights into genetic factors that enhance tumor-fighting abilities.

One of the most remarkable findings from this research was the identification of the RHOG gene as a critical target for increasing the potency of CAR T cells. Through systematic screening, the team discovered that the knockout of the RHOG gene led to a marked enhancement in the T cells’ abilities to combat leukemia in preclinical models. This insight underscores the complexity of CAR T cell functionality; while these cells have been engineered to perform a specific task, certain genetic factors that may bolster a natural immune response can paradoxically undermine their effectiveness in engineered forms, highlighting the nuanced interplay of genetics in immune response.

Eugenia Pankevich, a co-first author on the paper, elaborates on the significance of their findings. The researchers have demonstrated that certain genes, while crucial for natural immune functions, can hinder the effectiveness of CAR T therapies. By utilizing CRISPR technology to eliminate these counterproductive genetic components, the research team was able to enhance the overall therapeutic potential of CAR T cells significantly. This novel application of gene editing provides an exciting avenue for creating more effective cancer treatments that could drastically alter the prognosis for many patients.

In their pursuit of advancing CAR T cell therapy, the researchers employed their CELLFIE platform to evaluate the effects of thousands of gene knockouts comprehensively. In particular, they sought to identify genetic modifications that would allow the engineered T cells to persist longer in the body, resist exhaustion, and enhance their proliferative capacity when faced with tumor cells. The research incorporated an innovative in vivo CRISPR screening approach, corroborating the beneficial effects of specific genetic modifications in real-time within preclinical mouse models, a promising strategy that could streamline future clinical applications.

The discovery did not stop with the RHOG knockout. The team found that combining knockouts of RHOG with another gene known as FAS resulted in synergistic effects that significantly improved the therapeutic profile of CAR T cells. By knocking out both genes, the engineered cells demonstrated faster proliferation rates, increased activity levels, and a markedly greater ability to cure aggressive leukemia in murine models. This revelation opens up exciting possibilities for combinatorial genetic modifications in CAR T cell therapy, suggesting that a multi-target approach could enhance treatment outcomes even further.

Beyond immediate applications in blood cancers, the CELLFIE platform promises broader implications for immunotherapy. The technology presents a customizable framework capable of integrating genome-wide screenings and optimization protocols that aim to tailor immune therapies for a range of cancers, including traditionally harder-to-treat solid tumors. The potential to adapt these precision therapies further to address autoimmune disorders and regenerative medicine challenges presents a compelling opportunity for optimizing patient care based on individual genetic and immune profiles.

Christoph Bock, the principal investigator in the study, articulates the long-term vision for this research. By establishing a robust methodology for systematically enhancing cell-based immunotherapies, scientists are poised to pave the way for the next generation of immune therapies. As researchers delve deeper into understanding the programming of T cells as effective anti-cancer agents, the future of medicine may lie in these ‘living drugs’ that possess the ability to adapt and respond dynamically to various diseases.

The implications of this study are profound, particularly as clinical validation processes begin. The researchers are optimistic about undertaking clinical trials to assess the monumental potential of RHOG and FAS knockout CAR T cells in human subjects suffering from various forms of cancer. In particular, the promising synergy observed with dual gene knockouts could herald a new era of more effective treatments that incorporate multiple genetic targets.

As CAR T cell therapy continues to revolutionize cancer treatment landscapes, the prospects of enhancing efficacy through innovative genetic strategies like those outlined in this study may ultimately lead to broader applications and increased access for patients. With the introduction of CELLFIE and the promise of genetic modifications to enhance the power and persistence of CAR T cells, the boundaries of what is possible in cancer immunotherapy are expanding. This research not only enhances our understanding of the complexities of immune system dynamics but also represents a significant leap forward in the efficacy of personalized medicine.

As this field gains momentum, it is imperative for the scientific community to continue exploring these pathways. The evolution of CAR T cells into more effective therapies not only has the potential to save countless lives but also paves the way for re-imagining our approach to battling a wider spectrum of diseases. The intersection of genetics and immune therapy is rapidly evolving, with research like that conducted by the CeMM leading the charge towards a brighter future in oncology and beyond.

As the world eagerly awaits further developments in this exciting field, the researchers at CeMM and the Medical University of Vienna stand at the forefront of a transformative journey aimed at reshaping cancer treatment and improving patient outcomes through meticulous scientific exploration and innovation.

Subject of Research: Cells
Article Title: Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
News Publication Date: 24-Sep-2025
Web References: Nature Journal
References:
Image Credits: © Arc Institute; Wolfgang Däuble/CeMM

Keywords